miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)

BACKGROUND: Gliomas account for about 80% of all malignant brain and other central nervous system (CNS) tumors. Temozolomide (TMZ) resistance represents a major treatment hurdle. Adrenomedullin (ADM) has been reported to induce glioblastoma cell growth. METHODS: Cell viability was measured using the...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Zongze, Cheng, Meixiong, Hu, Junting, Liu, Lingtong, Liu, Ping, Chen, Longyi, Cao, Deqian, Tang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526964/
https://www.ncbi.nlm.nih.gov/pubmed/36183123
http://dx.doi.org/10.1186/s12967-022-03647-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526964/
https://www.ncbi.nlm.nih.gov/pubmed/36183123
http://dx.doi.org/10.1186/s12967-022-03647-6

Ejemplares similares